Abstract 223P
Background
Given the multiple treatment choices for advanced renal cell carcinoma (RCC), it is important to understand the treatment preferences of patients and physicians for the treatment of advanced RCC. This study aimed to understand patients’ and physicians’ preferences that influence their treatment choices for advanced RCC.
Methods
Qualitative interviews were conducted for 16 physicians and 10 advanced RCC patients in South Korea, Australia, Hong Kong and Taiwan. Physicians and patients each ranked 36 attributes related to treatment efficacy, side effects and mode of administration (score, 1-10) in terms of their preference for the treatment of advanced RCC. The scores of the top 10 attributes were aggregated among physicians and among patients to derive the overall score.
Results
For attributes related to treatment efficacy, physicians ranked years of survival (score =78), progression-free survival (score =78) and overall survival at 1 year (score =71) as most important, while patients ranked progression-free survival (score =54), years of survival (score =45), and duration of response (score =39) as most important. For attributes related to treatment side effects, physicians ranked grade 3 or 4 pneumonitis (score =40), chance of admission due to treatment side effects (score =37) and grade 3 or 4 gastrointestinal perforation (score = 33) as most important, while patients ranked grade 3 or 4 chronic kidney disease (score = 20), grade 3 or 4 myelosuppression (score =19) and chance of admission due to treatment side effects (score =17) as most important. The attributes prioritized by physicians did not differ by favourable vs intermediate/poor risk patient groups. Physicians and patients did not rank attributes related to mode of administration within the top 10.
Conclusions
Physicians and patients have slightly different preferences while making treatment choices. This study demonstrates that physicians and patients prioritized attributes related to treatment efficacy compared to side effects. A more effective dialogue between HCP and patient is needed to help decision-making in selecting the most appropriate treatment for advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA Solutions Asia Pte. Ltd.
Funding
MSD International GmbH, Singapore Branch.
Disclosure
N. Oliveira, B.C.W. Li, M. Kim, I. Park, Y. Su, C.K. Yang, A. Zhang, K.C.W. Wong: Financial Interests, Personal, Advisory Board: MSD. A. Dsouza: Financial Interests, Personal, Full or part-time Employment: MSD Singapore. S. Chua, E.M. Tan: Financial Interests, Personal, Full or part-time Employment, Commissioned to carry out this study (IQVIA): IQVIA Asia Pacific, Singapore. C. Spiteri: Financial Interests, Personal, Full or part-time Employment: MSD Australia.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract